Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Clostridioides difficile infection (CDI) (recurrent) is linked to an imbalance in the gut microbiota and poses a significant health challenge in the United States. RBX2660, a live biotherapeutic product, is composed of a diverse group of microbes derived from human stool. This product is currently being studied for its potential to reduce the recurrence of C. difficile infections (1).
A randomized, double-blind, placebo-controlled, phase III treatment trial evaluating RBX2660 or placebo in adults who had one or more Clostridioides difficile infection (CDI) (recurrent) …